Prognosis of Transthyretin Cardiac Amyloidosis Without Heart Failure Symptoms

BACKGROUND: Transthyretin amyloid cardiomyopathy (ATTR-CM) is increasingly recognized as a treatable cause of heart failure (HF). Advances in diagnosis and therapy have increased the number of patients diagnosed at early stages, but prognostic data on patients without HF symptoms are lacking. Moreov...

Descripción completa

Detalles Bibliográficos
Autores principales: Gonzalez-Lopez, Esther, Escobar-Lopez, Luis, Obici, Laura, Saturi, Giulia, Bezard, Mélanie, Saith, Sunil E., AbouEzzeddine, Omar F., Mussinelli, Roberta, Gagliardi, Christian, Kharoubi, Mounira, Griffin, Jan M., Dispenzieri, Angela, Vilches, Silvia, Perlini, Stefano, Longhi, Simone, Oghina, Silvia, Rivas, Adrian, Grogan, Martha, Maurer, Mathew S., Damy, Thibaud, Palladini, Giovanni, Rapezzi, Claudio, Garcia-Pavia, Pablo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elsevier 2022
Materias:
Mini-Focus Issue: Amyloidosis
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700255/
https://www.ncbi.nlm.nih.gov/pubmed/36444226
http://dx.doi.org/10.1016/j.jaccao.2022.07.007

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9700255/
https://www.ncbi.nlm.nih.gov/pubmed/36444226
http://dx.doi.org/10.1016/j.jaccao.2022.07.007

Ejemplares similares